%0
Generic
%T
Abstract CT028: Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study
%A Allan, John N.
%A Flinn, Ian W.
%A Siddiqi, Tanya
%A Ghia, Paolo
%A Tam, Constantine S.
%A Kipps, Thomas J.
%A Barr, Paul M.
%A Camburn, Anna Elinder
%A Tedeschi, Alessandra
%A Badoux, Xavier C.
%A Jacobs, Ryan
%A Kuss, Bryone J.
%A Trentin, Livio
%A Zhou, Cathy
%A Szoke, Anita
%A Naganuma, Maoko
%A Wierda, William G.
%I American Association for Cancer Research (AACR)
%@ 1538-7445
%K Cancer Research
%K Oncology
%D 2022
%C American Association for Cancer Research (AACR)